Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LEXXW 
Lexaria Bioscience Corp (LEXXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LEXXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.56% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.79M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 0.11 - 2.00 | Updated Date 04/17/2025 |
52 Weeks Range 0.11 - 2.00 | Updated Date 04/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1581.04% |
Management Effectiveness
Return on Assets (TTM) -77.6% | Return on Equity (TTM) -145.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 16302820 |
Shares Outstanding - | Shares Floating 16302820 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp. was founded in 2014 and focuses on drug delivery platforms, particularly its DehydraTECH technology. The company aims to improve the bioavailability of active pharmaceutical ingredients (APIs) and nutraceuticals.
Core Business Areas
- DehydraTECH Platform: Lexaria's core technology platform that enhances the oral bioavailability of various APIs, including cannabinoids, nicotine, and vitamins.
- Pharmaceutical R&D: Research and development efforts focused on utilizing DehydraTECH for specific pharmaceutical applications, such as hypertension and dementia.
- Licensing: Lexaria seeks to license its DehydraTECH technology to other companies for use in their products.
Leadership and Structure
Chris Bunka is the CEO. The organizational structure includes departments for research and development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- DehydraTECH Technology: A drug delivery platform that increases the bioavailability of active ingredients. Lexaria primarily focuses on licensing this technology to other companies. No defined market share. Competitors: Nanoemulsion technologies and liposomal encapsulation.
- Pharmaceutical Applications (Research Stage): Lexaria is researching the use of DehydraTECH in treating various conditions. Currently in preclinical and clinical trials. Competitors: Traditional pharmaceutical companies developing treatments for the same conditions.
Market Dynamics
Industry Overview
The drug delivery technology market is expanding, driven by the need for more effective and efficient drug administration methods. The nutraceuticals market is also a key growth area.
Positioning
Lexaria is positioned as a technology provider for improved drug delivery, focusing on enhancing bioavailability. Its competitive advantage lies in its DehydraTECH platform.
Total Addressable Market (TAM)
The global drug delivery market is expected to reach hundreds of billions of dollars. Lexaria aims to capture a portion of this TAM through licensing and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary DehydraTECH technology
- Potential for improved drug bioavailability
- Focus on licensing model
- Early-stage clinical trial success
Weaknesses
- Limited revenue generation
- Dependence on licensing agreements
- High R&D expenses
- Small market capitalization
Opportunities
- Expanding drug delivery market
- Increasing interest in cannabinoid-based therapies
- Potential partnerships with pharmaceutical companies
- Positive clinical trial results
Threats
- Competition from established drug delivery technologies
- Regulatory hurdles for new drug formulations
- Failure to secure licensing agreements
- Funding challenges
Competitors and Market Share
Key Competitors
- CRBP
- ABBV
- JNJ
Competitive Landscape
Lexaria faces competition from established pharmaceutical companies and other drug delivery technology providers. Its competitive advantage lies in the DehydraTECH platform's unique capabilities. Given Lexaria's licensing business model, most revenue potential is derived from other companies listed.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by preclinical and clinical trial progress rather than revenue.
Future Projections: Future growth depends on successful licensing agreements and pharmaceutical partnerships. Analyst estimates vary significantly based on these factors.
Recent Initiatives: Recent initiatives include clinical trials focusing on hypertension and dementia, and efforts to secure additional patents.
Summary
Lexaria Bioscience Corp. is a biotechnology company with a unique drug delivery platform, DehydraTECH, poised to enhance the bioavailability of active ingredients. Its success hinges on securing licensing agreements and advancing its pharmaceutical applications through clinical trials. While the technology holds promise, the company faces financial challenges and competition from established players. Positive clinical results and successful partnerships are critical for sustained growth. Lexaria's reliance on external funding and licensing revenue streams introduces uncertainty.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. SEC filings, press releases, company website, third-party financial data providers.
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided is based on publicly available information and analyst estimates, which are subject to change. Investing in Lexaria Bioscience Corp. involves significant risks, including the potential loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2021-01-12 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.